Member Info for BuenaVista

Quack Quack Quack Mooo Quack Baaa Quack

Maybe still a bit of work required.

Bill Gates slipped the word out you numpty. Didn't you get the email?

Just put your tinfoil helmet on and go back to your cupboard under the stairs.

Governments are going to block AVA6000 because Bill Gates runs the WHO?

NURSE!!!!!!!!!!

No not you nursesteve, you can stand down. We need the nurses that have the white jacket with the long straps.

Cuckoo! Cuckoo!

I suggest you revisit the presentation of the Science Day update on the AVA6000 trial
https://stream.brrmedia.co.uk/broadcast/63d3f8211874497653f33965/63f8f0edc6b3bd3a7295f995

and take a look in particular at slides 81 and 87 here
https://avacta.com/wp-content/uploads/2023/02/MASTER-DECK-Avacta-Science-Day-23.02.23_compressed-1.pdf

which between them explain the rationale for selecting the tumour types and which tumour indications Avacta be tackling first.

@Icecool,
https://avacta.com/wp-content/uploads/2022/04/Avacta-Group-plc-Prelim-Results-2021-FINAL.pdf

Slide 11

@icecool, I'm not sure the biopsies were taken from low FAP tumour types were they? They were certainly nearly all taken from tumour types that are not treated with doxorubicin as standard of care but that is because of doxorubicin's toxicity and the availability of other drugs which can be used.

Ask a stupid question. Demand an answer to the stupid question. And again. And take the spreadsheet home when there is no stupid answer given to the stupid question. Brilliant!

I was very disappointed at the way fairy dust got marginalised.

True

Avacta's already overpriced so suggest you take out a short on the shares if you want to trade.

Surely starting to recruit in the US at a leading major oncology centre worthy of a RNS?
Or are were already witnessing Avacta's new improved comms strategy? The one where they take every opportunity to avoid making a splash because... a deal at a fixed price has already been agreed and the SP needs to be kept down.

I've got to say I was expecting a bigger DE and a broader 'change' to the trial protocol, whatever that change is (nothing is showing on the trials website yet).

Firstly, if Avacta are going for only 2 more cohorts to actually find MTD then C6 would be something like 300mg/m² or, as Myles said, 312.5mg/m² which is 211mg/m² doxorubicin, or 3.5 times the standard 60mg/m² dose or 2.8 times the standard 75mg/m² dose. Still very high but I was hoping for even higher for a MTD as the higher the MTD, the greater the dosing regimen options for different cancers.

Secondly, the RNS mentions only MHRA and Phase 1a criteria. If it has taken AT LEAST ten weeks to get just MHRA approval for this change, I sincerely hope that the request for the very substantial change to Phase 1b was submitted at the same time to the MHRA, FDA and, if Europe means additional to the UK, EMA!

Will they? I don't think I'll see any apologies because I'd already put all those idiots on filter as they lack critical thinking and are far too emotional.

1.16%
Premier Fund Managers Limited 3,098,227 £3.6m -51.24% 0.05%

No TR1?

No HL?

I don't know where you got the data from but it is at odds with what's on the Avacta website.

Premier Miton Group – 4.66%
Baillie Gifford & Co Limited – 4.63%
Conifer Management, LLC – 2.99%
https://avacta.com/investors/key-information/

Incomplete edit! What's being waited for?

Just submitted:

Question 1
Why has there been a delay in starting cohort 5 of the AVA6000 trial? Lack of clarity about this, even whether the cohort has started, is causing uncertainty and doubt amongst investors. What are you waited for?

Question 2
The levels of doxorubicin in the biopsies vary considerably. Comments please on what affects the cleaving of AVA6000 within the TME that might account for this variation - proximity of the biopsy site to the delivering blood supply; tumour density; FAP expression in the tumour subtype (for the same cancer type); stage of the metastatic tumour (if there is such a thing); other...

Question 3
The AVA6000 side effects seem to be often linked to the GI tract (nausea, vomiting, appetite, constipation, diarrhoea). Is anything known (generally) about why particular people get particular side effects whilst other people don't get them? Everyone has rhythms to their body's metabolism throughout the day. Could the GI tract ones be related to time of day when AVA6000 was administered and/or to proximity to before or after taking meals/nutrients?

Question 4
What progress has been made on developing invitro diagnostics using Affimers?

Question 5
What is the Diagnostics Division's M&A strategy?
Acquisition of new tech? Device development? Manufacturing? Wider geographical coverage for distribution?
Timescale for these?

...and what the DE4 dose was.

Hmm... Frustrating for you perhaps to be in the dark but perhaps rather rash, foolhardy or even stupid for Alan to announce every intent before the outcome is known. Just take a moment to consider how the market would regard and judge a CEO who's full of talk but fails to deliver. If you were Avacta's CEO would you be telling the world what you intended to do and run that risk of failing? I don't think Alan is being overcautious after previous 'missteps', just sensible.

Strange. YOU have decided that FT/AA is in the pipeline and then you accuse Alan of not just not confirming your conclusion but also 'refusing' to talk about it (something in the pipeline, an egg rather than a chicken) when no one has actually raised the topic with him. And you already have 5 recs. I've come across this intuitively 'knowledgeable' thinking before. Are you all women?